Neuren completes brain injury drug trial

SYDNEY - Neuren Pharmaceuticals has successfully completed a safety and tolerability trial of its traumatic brain injury drug NNZ-2566.

Chief executive David Clarke said the trial on healthy volunteers was conformation that NNZ-2566 was safe.

Planning was now underway to test the drug on patients with traumatic brain injuries, which has a target market of US$1.5 billion ($2.18 billion) in the United States alone, Mr Clarke said.

Neuren is also exploring other opportunities for the drug such as vascular dementia and stroke-related injuries.

- AAP